Bruker (BRKR) Competitors

Bruker currently has a consensus target price of $59.43, suggesting a potential upside of 5.11%. Mettler-Toledo International has a consensus target price of $1,469.15, suggesting a potential downside of 10.42%. Given Bruker's stronger consensus rating and higher possible upside, equities research analysts plainly believe Bruker is more favorable than Mettler-Toledo International.

In the previous week, Bruker and Bruker both had 10 articles in the media. Mettler-Toledo International's average media sentiment score of 0.69 beat Bruker's score of 0.57 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Mettler-Toledo International has a net margin of 21.91% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Mettler-Toledo International's return on equity.

Bruker has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Mettler-Toledo International has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

79.5% of Bruker shares are held by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are held by institutional investors. 27.2% of Bruker shares are held by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Bruker had 6 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Bruker and 4 mentions for Revvity. Bruker's average media sentiment score of 0.57 beat Revvity's score of 0.27 indicating that Bruker is being referred to more favorably in the media.

79.5% of Bruker shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 27.2% of Bruker shares are owned by company insiders. Comparatively, 0.9% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Revvity has a net margin of 8.16% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Revvity's return on equity.

Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.4%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bruker pays out -28.6% of its earnings in the form of a dividend. Revvity pays out 13.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker is clearly the better dividend stock, given its higher yield and lower payout ratio.

Revvity has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Bruker presently has a consensus price target of $59.43, indicating a potential upside of 5.11%. Revvity has a consensus price target of $124.43, indicating a potential downside of 19.57%. Given Bruker's stronger consensus rating and higher possible upside, analysts plainly believe Bruker is more favorable than Revvity.

Bruker has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Revvity has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 27.2% of Bruker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Thermo Fisher Scientific had 19 more articles in the media than Bruker. MarketBeat recorded 29 mentions for Thermo Fisher Scientific and 10 mentions for Bruker. Thermo Fisher Scientific's average media sentiment score of 1.25 beat Bruker's score of 0.57 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Thermo Fisher Scientific currently has a consensus target price of $654.05, suggesting a potential downside of 5.99%. Bruker has a consensus target price of $59.43, suggesting a potential upside of 5.11%. Given Bruker's higher possible upside, analysts clearly believe Bruker is more favorable than Thermo Fisher Scientific.

Thermo Fisher Scientific has a net margin of 15.04% compared to Bruker's net margin of -2.35%. Thermo Fisher Scientific's return on equity of 17.09% beat Bruker's return on equity.

Thermo Fisher Scientific has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Bruker has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Thermo Fisher Scientific has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Thermo Fisher Scientific pays an annual dividend of $1.88 per share and has a dividend yield of 0.3%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.4%. Thermo Fisher Scientific pays out 10.1% of its earnings in the form of a dividend. Bruker pays out -28.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has increased its dividend for 8 consecutive years. Bruker is clearly the better dividend stock, given its higher yield and lower payout ratio.

Waters has higher earnings, but lower revenue than Bruker. Bruker is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

In the previous week, Bruker had 3 more articles in the media than Waters. MarketBeat recorded 10 mentions for Bruker and 7 mentions for Waters. Bruker's average media sentiment score of 0.57 beat Waters' score of 0.39 indicating that Bruker is being referred to more favorably in the news media.

Waters has a net margin of 3.58% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Waters' return on equity.

Waters has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Bruker has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Waters presently has a consensus target price of $443.79, indicating a potential downside of 0.25%. Bruker has a consensus target price of $59.43, indicating a potential upside of 5.11%. Given Bruker's higher possible upside, analysts clearly believe Bruker is more favorable than Waters.

94.0% of Waters shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 0.3% of Waters shares are held by company insiders. Comparatively, 27.2% of Bruker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.